Sector | Healthcare | Compare with Sector peers |
Industry | Pharmaceuticals & Drugs | Compare with Industry peers |
Website | http://www.concorddrugs.in | |
Market Cap | 35.17 Cr. | |
Enterprise Value(EV) | 52.06 Cr. | 2023-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 0.98 | Trailing Twelve Months Ending 2023-12 |
Price-Earning Ratio (PE) | 36.07 | Trailing Twelve Months Ending 2023-12 |
Industry PE | 41.54 | Trailing Twelve Months Ending 2023-12 |
Book Value / Share | 35.16 | Trailing Twelve Months Ending 2023-12 |
Price to Book Value | 1.00 | Calculated using Price: 35.17 |
Dividend Yield | 0.00 | Period Ending 2023-03 |
No. of Shares Subscribed | 1.00 Cr. | 10,000,000 Shares |
FaceValue | 10 | |
About Concord Drugs Ltd. | ||
Concord Drugs is engaged in developing new products Viz MUPS (Multiple Unit Pellet System), Sustained Release, Modified Release pellets with Innovative Drug Delivery Technologies by utilizing best and latest processing machinery. |
1 Day |
|
-0.56% |
1 Week |
|
+1.28% |
1 Month |
|
-9.73% |
3 Month |
|
-17.42% |
6 Month |
|
+8.02% |
1 Year |
|
+32.27% |
2 Year |
|
+19.40% |
5 Year |
|
+68.00% |
10 Year |
|
2 years | 2022-03 | 2023-03 | |
Return on Equity (%) | 5.62 | 3.31 | |
Return on Capital Employed (%) | 8.77 | 6.32 | |
Return on Assets (%) | 2.82 | 1.72 |
Particulars | 3 years | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
Shh. Funds | 28 | 32 | 33 | |
Non Curr. Liab. | 4 | 5 | 5 | |
Curr. Liab. | 24 | 22 | 21 | |
Minority Int. | ||||
Equity & Liab. | 56 | 58 | 59 | |
Non Curr. Assets | 15 | 15 | 14 | |
Curr. Assets | 42 | 43 | 45 | |
Misc. Exp. not W/O | ||||
Total Assets | 56 | 58 | 59 |
Particulars | 3 years | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
Net Sales | 59 | 52 | 42 | |
Other Income | 0 | 0 | ||
Total Income | 59 | 52 | 42 | |
Total Expenditure | -53 | -48 | -37 | |
PBIDT | 6 | 5 | 5 | |
Interest | -2 | -2 | -2 | |
Depreciation | -2 | -2 | -1 | |
Taxation | -1 | 0 | 0 | |
Exceptional Items | ||||
PAT | 2 | 1 | 1 | |
Minority Interest | ||||
Share Associate | ||||
Other Related Items | ||||
Consolidated Net Profit | 2 | 1 | 1 | |
Adjusted EPS | 2 | 1 | 1 |
Particulars | 2 years | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Cash Fr. Operatn. | 1 | 2 | |
Cash Fr. Inv. | -2 | -2 | |
Cash Fr. Finan. | 2 | 1 | |
Net Change | 0 | 0 | |
Cash & Cash Eqvt | 0 | 0 |
Tue, 19 Mar 2024
Board Meeting Outcome for Appointment Of Company Secretary Cum Compliance Officer Appointment of Ms. Namratha Nagla (ACS-68979) as Company Secretary Cum Compliance Officer |
Tue, 19 Mar 2024
Appointment of Company Secretary and Compliance Officer Appointment of Ms. Namratha Nagla as Company Secretary Cum Compliance Officer |
Tue, 13 Feb 2024
Un-Audited Financial Results (Standalone And Consolidated) For The Quarter Ended 31St December 2023. Un audited results (standalone and consolidated for the quarter ended 31.12.2023 |
Thu, 28 Mar 2024 |
Close Below Last Month Low |
High Decrease in 1 Month |
High Decrease in 3 Months |
High Increase in 1 Year |
Doji and Near Doji |